Publication: Nanopore IDs >50 genetic diseases
Researchers use Oxford Nanopore technology to develop a single test method to characterise more than 50 genetic diseases
In a study published in Science Advances, a team from the Garvan Institute of Medical Research, Australia, has described how their method using nanopore sequencing technology has the potential to reduce the 'diagnostic odyssey' for people with rare neurological and neuromuscular disease
A new DNA sequencing-based test method developed by a team led by Ira Deveson, Head of Genomics Technologies at the Garvan Institute of Medical Research, and collaborators, has been shown to have the potential to screen for more than 50 genetic neurological and neuromuscular diseases. In research, this new workflow accurately identifies diseases caused by unusually long, repetitive DNA sequences in a person's genes, known as short tandem repeat (STR) expansion disorders. Current genetic screening for these disorders can involve multiple tests, such as muscle or nerve biopsies, and take much longer, sometimes years of investigation to reach an answer.
The STR repeat expansions typically span a longer region of DNA than the read lengths generated by short-read sequencing technology. To overcome this, the research teams used Oxford Nanopore technology, which can read fragments of any length and can be programmed to target specific regions of DNA. During a recent presentation [available here ] on this work Ira Deveson described long-read nanopore technology as 'the ideal tool'. He went on to discuss the future potential for nanopore sequencing to 'solve the problem in one step' by reading STRs end-to-end in single long reads.
In the published study the team describe how they achieved accurate molecular characterisation of all known neuropathogenic STRs in a single workflow, as well as DNA methylation, with no additional library preparation or costs. Once validated using nanopore sequencing to target specific regions of interest may also be useful to guide personalised selection of medications.
This research demonstrates the potential for nanopore sequencing in disease characterisation and the study discusses how this could be a powerful approach for STR gene discovery for previously unsolved cases as well.
The full Science Advances publication is available here .
-end-
Contact: media@nanoporetech.com
About Oxford Nanopore Technologies
Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 100 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments.
Oxford Nanopore Technologies, the Wheel icon, EPI2ME, Flongle, GridION, Metrichor MinION, MinKNOW, PromethION, SmidgION, Ubik and VolTRAX are registered trademarks of Oxford Nanopore Technologies plc in various countries. All other brands and names contained are the property of their respective owners. © 2022 Oxford Nanopore Technologies plc. All rights reserved. Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose, treat, mitigate, cure, or prevent any disease or condition.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 4 hours ago ASOS
- 5 hours ago MJ Gleeson
- 5 hours ago Rolls-Royce Holdings
- 5 hours ago Crest Nicholson Holdings
- 6 hours ago Naked Wines